Udayakumar Navaneethan, MD
Gastroenterology · Saint Petersburg, FLNPI 1225227507
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $887,145 of the $1,078,877 with a category attached, or 82.2%. It is spread thinly across 23 manufacturers, the largest accounting for just 21.4%. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 911 payments — averaging $1184.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$231K
- Lilly USA, LLC$196K
- AbbVie$184K
- Takeda Pharmaceuticals U.S.A., Inc.$131K
- E.r. Squibb & Sons, L.L.C.$105K
- Pfizer$95K
- plus $136K from 17 others
Across 253 payments — averaging $4359.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$276K
- Janssen Research & Development, LLC$222K
- Eli Lilly$175K
- Gilead$147K
- AbbVie$70K
- Genentech, Inc.$66K
- plus $146K from 6 others
What the payments were for
- Consulting fees$73,4457%
- Speaking & faculty fees$887,14582%
- Travel & lodging$102,83110%
- Food & beverage$15,2841%
- Education$1720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 161 | $230,921 |
| Lilly USA, LLC | 165 | $196,293 |
| AbbVie | 234 | $183,722 |
| Takeda Pharmaceuticals U.S.A., Inc. | 69 | $131,476 |
| E.r. Squibb & Sons, L.L.C. | 45 | $105,474 |
| Pfizer | 84 | $94,675 |
| Janssen Scientific Affairs, LLC | 50 | $67,052 |
| Celltrion USA Inc. | 48 | $54,929 |
| Eli Lilly | 4 | $7,743 |
| Ipsen Biopharmaceuticals, Inc | 1 | $3,320 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $1,256 |
| Boston Scientific | 8 | $656 |
| Bristol Myers Squibb | 23 | $466 |
| Olympus America Inc. | 4 | $219 |
| 3-d Matrix, Inc. | 1 | $177 |
| Braintree Laboratories, Inc. | 1 | $135 |
| Ferring Pharmaceuticals Inc. | 5 | $123 |
| Covidien LP | 1 | $113 |
| Conmed Corporation | 1 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $29 |
| Apollo Endosurgery US Inc | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,078,877 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 265 | $7,079,031 |
| RinvoqUpadacitinib | 139 | $1,128,294 |
| GattexTeduglutide | 22 | $1,023,572 |
| Skyrizi On-BodyRisankizumab-Rzaa | 45 | $923,973 |
| Humira(Cf) PenAdalimumab | 53 | $454,337 |
| RemicadeInfliximab | 16 | $103,729 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 54 | $8,674 |
| Ondansetron Hcl | 12 | $5,111 |
| Colestipol Hcl | 29 | $2,676 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 37 | $2,265 |
| Colesevelam Hcl | 15 | $2,020 |
| LoperamideLoperamide Hcl | 32 | $1,382 |
| Balsalazide Disodium | 16 | $1,177 |
| Budesonide DrBudesonide | 12 | $1,105 |
| Mesalamine | 14 | $835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $230,921 | $7,182,760281 claims |
| AbbVieRinvoq | $183,722 | $1,128,294139 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $131,476 | $1,023,57222 claims |
| Braintree Laboratories, Inc.Sutab | $135 | $8,67454 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Saint Petersburg
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
- Peter DraganovGainesville$832K
- Arin NewmanMiami Beach$716K
- Joanna LopezMiami$670K
- Jose NietoSebring$573K
- Jerry MartelMiami$511K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.